The 2024 Edibles & Minor Cannabinoid Market Report is now available.
Fuel your business growth with critical insights into the expanding
minor cannabinoid-infused edibles market in 13 key regulated states.
BayMedica Products
.
Elevate Your Products with Our cGMP Cannabinoids
Our family of nature-identical synthesized minor cannabinoids, such as CBC, THCV, CBDV, and CBT, is produced at commercial scale under food-grade Current Good Manufacturing Practices (cGMP), ensuring unparalleled purity, consistency, and safety.
Incorporating our rare cannabinoids into your products ensures compliance with rigorous industry standards, streamlines regulatory processes, and enhances consumer confidence in your brand.
Seamlessly integrate our premium, rare cannabinoids into your consumer health and wellness products to gain a competitive edge.
The BayMedica Platform
Biosynthesis is a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products. Cannabinoids are one class of compounds synthesized by Cannabis, however, the Cannabis sativa plant is an inefficient biological factory for even the most prevalent compounds such as THC and CBD, which comprise only 2-5% of the biomass of the plant. Cannabis is even less efficient at synthesizing the 100+ minor cannabinoids such as CBC, CBN and CBDV that typically comprise less than 0.1% of plant biomass.
The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. Our platform produces rare, non-intoxicating, naturally-occurring cannabinoids and novel cannabinoid analogs. We also leverage our experience in synthetic chemistry where applicable. BayMedica cannabinoids have a wide variety of applications in the pharmaceutical, cosmetic, consumer and animal health industries.
.
BayMedica Is A Subsidiary of InMed Pharmaceuticals
InMed is a global leader in the manufacturing and development of rare cannabinoids. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed is a publicly traded company, listed on the Nasdaq exchange under the symbol INM.